Jaguar Health to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer

Jaguar Health, Inc. has announced its intention to pursue regulatory approval for Crofelemer based on Phase 3 results. The company is focusing on breast and lung cancer patients following meaningful clinical outcomes reported in its OnTarget trial. The trial examined prophylaxis of diarrhea in adult cancer patients receiving targeted therapy.

In a letter to shareholders, CEO Lisa Conte detailed plans for a webcast on August 13, 2024, to review Q2 earnings and discuss the next steps. Jaguar also noted that Crofelemer has shown benefits in other conditions, including inflammatory bowel syndrome and short bowel syndrome in pediatric patients in Abu Dhabi.

The approval pathway exploration follows Crofelemer's previous FDA approval for noninfectious diarrhea in HIV/AIDS patients. Jaguar aims to leverage this experience for new indications in breast and lung cancer-related diarrhea.